Means a compound produced in the preparation (1) of Phthaloyl hydrazide pyridinopyridine phthalate, wherein R1 is a compound (a) or (b) of the formula,Where R2 and R4 are alternative alcoxi (C1-C4) and alcoxi (C1-C4), respectively, replaced by F； R3 is alcoxi (C1-C4),Cyclooxygenation (C3-C5),R5 is a kind of asphalt (C1-C4)；R6 is h or tar (C1-C4)；R7 is h； R8 is asphalt (C1-C4)；R9 is h or tar (C1-C4)；R10 is h, cycloquilo (C5-C7),1. Asphalt (C1-C6),R17 is h or methyl, R18 is CH2 cycloquilo (C3-C6)；R19 is h, hydroxy, alcoxi (C1-C4),Among other things, R20 is h, alcoxi (C1-C4),M is 1 or 2, among other things. - 1 -, 1 -, 1 -, 1 -, 1 -, 1 -, 1 -, 1 -, 1 -, 1-carbohydrates； 4 - [2 - (cycloacrylonitrile) - 5-fluoro-4-methoxy] n - [(2S) - 1 - {4 - [(4S, 8ar) - 4 - (3), 4. Dimethoxyphenyl-1-oxo-4a, 5, 6, 7, 8, 8a-hexahydropalazin-2 (1h-il) piseridin-1-il} - 3 - (3-methylphenyl) - 1-oxopropan-2-il] - 6-methyl-5h-pirrolo [3, 2-D] pirimidine-7-carboxamida；There are others He also mentioned a pharmaceutical composer These compounds are class 4 and class 5 phosphate mixed inhibitors for the treatment of pulmonary pore disease, pulmonary fibrosis, and cystic fibrosis.SE REFIERE A COMPUESTOS DERIVADOS DE FTALAZINONA-PIRROLOPIRIMIDINACARBOXAMIDADE FORMULA (1) DONDE R1 ES UN COMPUESTO DE FORMULA (a) O (b), EN DONDE R2 Y R4 SON CADA UNO ALCOXI(C1-C4) OPCIONALMENTE SUSTITUIDO CON F； R3 ES ALCOXI(C1-C4), CICLOALCOXI(C3-C5), ENTRE OTROS； R5 ES ALQUILO(C1-C4)； R6 ES H O ALQUILO(C1-C4)； R7 ES H； R8 ES ALQUILO(C1-C4)； R9 ES H O ALQUILO(C1-C4)； R10 ES H, CICLOALQUILO(C5-C7), ALQUILO(C1-C6), ENTRE OTROS； R17 ES H O METILO； R18 ES CH2-CICLOALQUILO(C3-C6)； R19 ES H, HIDROXILO, ALCOXI(C1-C4), ENTRE OTROS； R20 ES H, ALCOXI(C1-C4), ENTRE OTROS； m ES 1 O 2. SON COMPUESTOS PREFERIDOS: 4-[5-(CICLOPROPILMETOXI)-1,3-BENZODIOXOL-4-IL]-N-[(2R)-3-(3,5-DIFLUOROFENILO)-1-{4-[(4aS,8aR)-4-(3,4-DIMETOXIFENILO)-1-oxo-4a,5,6,7,8,8a-HEXAHIDROFTALAZIN-2(1H)-IL]PIPERIDIN-1-IL}-1-OXOPROPAN-2-IL]-5H-PIRROLO[3,2-d]PIRI
